Physician profile
Aaron Domm
NPI 1760527576
$2,201.40
in general payments reported to CMS, 2019-2025
30 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $135 · 2021: $224 · 2022: $283 · 2023: $426 · 2024: $479 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.65 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Pfizer INC. | $242.62 | 2019-2025 | |
| Genzyme Corporation | $192.66 | 2022-2025 | |
| Janssen Biotech, INC. | $106.69 | 2019-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $74.38 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $72.08 | 2022-2023 | Watchman, Watchman Flx, Spectra Wavewriter |
| Gilead Sciences, INC. | $69.05 | 2020-2025 | |
| Braintree Laboratories, INC. | $66.12 | 2021-2025 | Suflave, Sutab |
| Celgene Corporation | $63.45 | 2022-2024 | Zeposia |
| Novo Nordisk INC | $61.58 | 2025 | Wegovy |
| Redhill Biopharma INC. | $60.75 | 2021 | |
| Phathom Pharmaceuticals, INC. | $54.08 | 2025 | Voquezna |
| Organon LLC | $49.92 | 2023-2025 | Hadlima, Renflexis |
| Takeda Pharmaceuticals U.S.A., INC. | $48.52 | 2021-2024 | Entyvio |
| Axonics, INC. | $45.89 | 2022-2024 | Axonics |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $41.60 | 2021-2022 | |
| Lilly USA, LLC | $38.15 | 2024-2025 | Omvoh |
| Peerless Surgical INC. | $36.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.89 | 2024-2025 | Relistor, Xifaxan |
| Aimmune Therapeutics, INC. | $25.49 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $25.15 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $19.75 | 2025 | Iqirvo |
| Qol Medical, LLC | $19.73 | 2023 | Sucraid |
| Curonix LLC | $17.93 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Hospira, INC. | $16.38 | 2019 | |
| Shionogi INC | $14.46 | 2019 | |
| Madrigal Pharmaceuticals | $13.18 | 2024 | Resmetirom |
| Alfasigma USA, INC. | $11.88 | 2020 | |
| Merck Sharp & Dohme LLC | $11.65 | 2020 | |
| Romark Laboratories, Lc | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Domm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.